Amyloid PET | |||
---|---|---|---|
Positive | Negative | p-value | |
Median (IQR) or N (%) | |||
N = 174 | 65 (37.4%) | 109 (62.6%) | |
Age | 75 (70–80) | 69 (60–75) | < 0.001 |
Sex, No. of men/women | 33/32 (50.8%) | 53/56 (48.6%) | 0.784 |
APOE ɛ4, No. of positive participants (%) | 36/29 (55.4%) | 25/84 (22.9%) | < 0.001 |
MMSE scorea | 24 (21–27.5) | 29(26–30) | < 0.001 |
ADAS-Cog scoreb | 11.2 (6.3–20.0) | 4.7 (3.1–7.5) | < 0.001 |
Aβ42/40 (× 10–2) | 8.49 (8.23–8.87) | 10.9 (10.2–11.3) | < 0.001 |
p-tau181 (pg/ml)c | 3.47 (2.58–4.31) | 1.73 (1.32–2.33) | < 0.001 |
GFAP (pg/ml)d | 365 (281–542) | 213 (162–283) | < 0.001 |
NfL (pg/ml)e | 25.4 (19.6–32.8) | 18.8 (15.1–25.8) | < 0.001 |
Clinical diagnosis | < 0.001 | ||
HC | 10 (15.4%) | 48 (44.0%) | |
MCI | 23 (35.4%) | 20 (18.3%) | |
AD | 27 (41.5%) | 5 (4.6%) | |
FTLD | 4 (6.2%) | 20 (18.3%) | |
DLB/PD | 1 (1.5%) | 4 (3.7%) | |
Others | 0 (0%) | 12 (11.0%) |